AR-NADR

AR-NADR is a dual-targeting nanocarrier system designed for the treatment of cisplatin-resistant hepatocellular carcinoma (HCC). It consists of a core made from metal–organic frameworks (MOF) modified with a nuclear localization sequence (NLS), loaded with cisplatin (DDP) and NOR1 shRNA, and is coated with an A54 peptide-inserted erythrocyte membrane. The A54 peptide targets receptors abundantly expressed on HCC cells, while the NLS promotes nuclear entry. The system enables targeted delivery of both chemotherapy and gene therapy, combining intracellular delivery of cisplatin and gene silencing of NOR1 to reverse drug resistance. The shell provides immune escape and improved biocompatibility, and the MOF core releases cisplatin more efficiently in the acidic tumor microenvironment. This precise chemotherapeutic and gene therapy approach is intended to overcome resistance to cisplatin in hepatocellular carcinoma by reducing NOR1-mediated drug resistance and increasing cisplatin accumulation in tumor cells[1].